Hormone Resistant Prostate Cancer Terminated Phase 2 Trials for Selinexor (DB11942)

Also known as: Hormone-Resistant Prostate Cancer

IndicationStatusPhase
DBCOND0038482 (Hormone Resistant Prostate Cancer)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02215161Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate CancerTreatment